TheEdgeResearch
Home / Stocks / FNCH

Finch Therapeutics Group, Inc. (FNCH)

OTC Healthcare Biotechnology
$10.20 ▲ +0.99%
Market Cap
$16.4M
Sector
Healthcare
Industry
Biotechnology
Beta
1.48
52-Wk Range
2-16.1
CEO
Matthew Blischak
Country
US
Currency
USD

Finch Therapeutics Group, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $10.20, up 0.99% on the session, giving a market capitalisation of $16.4M. On trailing twelve-month figures it carries a trailing P/E of -1.18, a net margin of 0.0%. Its beta of 1.48 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-1.18
Price / Sales
0.00
Price / Book
1.80
EV / EBITDA
-2.47
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
3.06
Current ratio
3.39
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
2021-03-19
Headquarters
Boston, MA, US
About Finch Therapeutics Group, Inc.

Finch Therapeutics is a microbiome technology company with a portfolio of intellectual property and microbiome assets. The company is now focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations after winding down development efforts.

Comparable companies

Finch Therapeutics Group, Inc. is most often compared with the following Healthcare names:

BMEACNTBEWTXHOWLIMAKTTAQNRX
More research on FNCH
FNCH technical analysis FNCH TheEdge Score Compare against peers
Open full interactive analysis & DCF →